MedTrace Logo

A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

NCT02608684 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-03-23

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab IV solution

DRUG

Gemcitabine

Gemcitabine IV solution

DRUG

Cisplatin

Cisplatin IV solution

Sponsors & Collaborators

Principal Investigators

  • Bobbie J Rimel, MD · Cedars-Sinal Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-08
Primary Completion
2019-05-17
Completion
2022-03-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608684 on ClinicalTrials.gov